Early dialogue between the developers of new technologies and pricing and reimbursement agencies: A pilot study

Value in Health

Volumn 14, Issue 4, 2011, Pages 608-615

  Backhouse, Martin E ^a   Wonder, Michael ^b   Hornby, Edward ^a   Kilburg, Anne ^a   Drummond, Michael ^c   Mayer, Friedrich Karl ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Teva Pharmaceuticals Australia Pty Ltd   (Australia)

^c UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Clinical research; Cost effectiveness analysis; Decision making; Payer direct engagement; Pharmaceuticals

Indexed keywords

ADALIMUMAB; COAL TAR; CORTICOSTEROID; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; FUMARIC ACID ETHYL ESTER; INFLIXIMAB; METHOTREXATE; RETINOL DERIVATIVE; VITAMIN D DERIVATIVE;

ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; DECISION MAKING; DRUG INDUSTRY; DRUG INFORMATION; DRUG MANUFACTURE; HEALTH CARE INDUSTRY; HEALTH CARE ORGANIZATION; HUMAN; PILOT STUDY; PRIORITY JOURNAL; PSORIASIS VULGARIS; PUVA; QUALITY OF LIFE; REIMBURSEMENT;

EID: 79959959327     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2010.11.011     Document Type: Article

References (10)

1. International Society of Pharmacoeconomics and Outcomes Research (ISPOR). Pharmacoeconomic guidelines around the world. 2010. Available from: www.ispor.org [Accessed February 1, 2010].
2. Drummond MF, Evans B, LeLorier J, et al. Evidence and values: requirements for public reimbursement of drugs for rare diseases - a case study in oncology. Can J Clin Pharmacol 2009;16: e273-81.
3. Trotta F, Apolone G, Garattini S, Tafuri G. Stopping a trial early in oncology: for patients or for industry? Ann Oncol 2008;19:1347-53. (Pubitemid 351972203)
4. Fleming TR, Rothmann MD, Lu HL. Issues in using progression-free survival when evaluating oncology products. J Clin Oncol 2009;27:2874-80.
5. Backhouse ME. Raising the standards of trial-based economic evaluation: the devil is in the detail. Value Health 2005;8:519-20. (Pubitemid 41727303)
6. Ades A, Sculpher M, Sutton A, et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 2006;24:1-19. (Pubitemid 43197227)
7. Neumann PJ, Drummond MF, Jönsson B, et al. Are key principles for improved health technology assessment supported and used by health technology assessment organizations? Int J Technol Assess Health Care 2010;26:71-8.
8. Drummond MF. Should commercial-in-confidence data be used by decision makers when making assessments of cost-effectiveness? Applied Health Econ Health Policy 2002;1:53-4.
9. Eichler H-G, Bloechl-Daum B, Abadie E, et al. Relative efficacy of drugs: an emerging issue between regulators and third-party payers. Nature Rev Drug Discovery 2010;9:277-91.
10. Ljungberg B. Presentation at the Health Technology Assessment International (HTAi) Annual Conference. Dublin, Ireland; June 2010.